This article is more than 5 years old. Information may no longer be current.

VIDEO: Development of tumor lysis syndrome with venetoclax leads to dose ramp-up schedule

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The occurrence of tumor lysis syndrome in the clinical trial that led to approval of venetoclax for relapsed CLL with deletion of 17p has resulted in a dose ramp-up schedule for the agent, according to Ryan W. Jacobs, MD, of the Carolinas HealthCare System’s Levine Cancer Institute.

Jacobs describes the occurrence of tumor lysis syndrome during the trial and the dose ramp-up schedule that was developed. Although venetoclax (Venclexta; AbbVie, Genentech) is an oral agent, the time to initiate treatment “will be more significant” than the time needed for other kinase inhibitors used in CLL.

“The current FDA approval is now specific enough to highlight certain patient groups that will also require hospitalization as part of treatment initiation with this agent,” Jacobs said.